- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Surrozen secures patent for tissue repair technology | 1 | Investing.com | ||
| 14.05. | Surrozen, Inc.: Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway | 155 | GlobeNewswire (Europe) | Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating... ► Artikel lesen | |
| 09.05. | Surrozen GAAP EPS of -$7.43 misses by $5.65, revenue of $0.98M | 1 | Seeking Alpha | ||
| 09.05. | Surrozen, Inc./DE - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update | 820 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively... ► Artikel lesen | |
| 09.05. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc./DE - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| SURROZEN Aktie jetzt für 0€ handeln | |||||
| 31.03. | Surrozen, Inc./DE - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc.: Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates | 51 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the... ► Artikel lesen | |
| 31.03. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Surrozen, Inc./DE - 8-K, Current Report | 2 | SEC Filings | ||
| 24.03. | Surrozen shifts focus to eye disease treatments, secures $175M funding | 1 | Investing.com | ||
| 24.03. | Surrozen, Inc.: Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases | 1 | GlobeNewswire (USA) | ||
| 24.03. | Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease | - | FierceBiotech | ||
| 06.11.24 | Surrozen, Inc.: Surrozen Provides Third Quarter 2024 Financial Results and Business Update | 387 | GlobeNewswire (Europe) | Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio... ► Artikel lesen | |
| 12.08.24 | Surrozen, Inc.: Surrozen Provides Second Quarter 2024 Financial Results and Business Update | 996 | GlobeNewswire (Europe) | Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,15 | -0,11 % | Novo Nordisk, BioNxt Solutions, BioNTech - so heilen Sie Ihr Portfolio mit der Gesundheits-Revolution 2025 | Das globale Gesundheitswesen erlebt 2025 eine Zeitenwende. Klimafolgen, chronische Krankheiten und Pandemienarben fordern Systeme heraus, während Digitalisierung und KI rasant neue Therapien vorantreiben.... ► Artikel lesen | |
| EVOTEC | 6,216 | -16,63 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| CUREVAC | 4,600 | -0,26 % | UNGLAUBLICHE Sondermeldung bei CureVac Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| AMGEN | 254,65 | +0,61 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,400 | +0,50 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,460 | +3,37 % | NurExone Biologic: Nominiert von der "Falling Walls Foundation" in Berlin! | ||
| IBIO | 0,570 | 0,00 % | XFRA DIVERSE ISINS: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 12,680 | +0,79 % | Arrowhead hits the skids due to partnership with Sarepta | ||
| COHERUS ONCOLOGY | 0,797 | +5,12 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,674 | -1,26 % | Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach | - New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly-owned... ► Artikel lesen | |
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 1,420 | -2,74 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis | NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 17,138 | +3,93 % | Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) | ||
| CYBIN | 6,900 | +0,73 % | Cybin Inc.: Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder | - EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will... ► Artikel lesen | |
| BENITEC BIOPHARMA | 11,130 | +0,72 % | Benitec Biopharma Inc.: Benitec Biopharma Provides Operational Updates | -In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring... ► Artikel lesen |
Das Unternehmen SURROZEN INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+0,94 %) liegt der Kurs bei 8,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SURROZEN INC finden Sie auf Wallstreet Online.